AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Inify Laboratories AB Director's Dealing 2025

Jan 30, 2025

6123_rns_2025-01-30_3cb65907-8b4f-4aad-ad9a-d9fac28a53aa.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, January 30, 2025; Inify Laboratories AB (publ.) has been notified that the following transactions have been completed by a primary insider in Inify; Olof Sandén, board member and primary insider in Inify, has acquired 16,840 shares in Inify at an average price of SEK 4.36 per share during January 27th – 29th. After the transactions, Sandén controls 116,840 shares.

This information is subject to the disclosure requirements pursuant to the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact CEO, Fredrik Palm, [email protected], or visit https://www.inify.com.

###

About Inify Laboratories

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.